- Home
- Publications
- Publication Search
- Publication Details
Title
Small molecule-based immunomodulators for cancer therapy
Authors
Keywords
-
Journal
Acta Pharmaceutica Sinica B
Volume 12, Issue 12, Pages 4287-4308
Publisher
Elsevier BV
Online
2022-11-12
DOI
10.1016/j.apsb.2022.11.007
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeting toll-like receptors on T cells as a therapeutic strategy against tumors
- (2022) Renyi Ding et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Design, synthesis, and biological evaluation of triazole-pyrimidine-methylbenzonitrile derivatives as dual A2A/A2B adenosine receptor antagonists
- (2022) Zhi Li et al. JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY
- Targeting CD73 with AB680 (Quemliclustat), a Novel and Potent Small-Molecule CD73 Inhibitor, Restores Immune Functionality and Facilitates Antitumor Immunity
- (2022) Dana Piovesan et al. MOLECULAR CANCER THERAPEUTICS
- Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor
- (2022) Holly K. Koblish et al. Cancer Discovery
- Novel phthalimides regulating PD-1/PD-L1 interaction as potential immunotherapy agents
- (2022) Chengliang Sun et al. Acta Pharmaceutica Sinica B
- STING as an emerging therapeutic target for drug discovery: Perspectives from the global patent landscape
- (2022) Xiangjun Kong et al. Journal of Advanced Research
- Dual-target inhibitors of indoleamine 2, 3 dioxygenase 1 (Ido1): A promising direction in cancer immunotherapy
- (2022) Ya Zhang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Discovery and Characterization of a Novel Aryl Hydrocarbon Receptor Inhibitor, IK-175, and Its Inhibitory Activity on Tumor Immune Suppression
- (2022) Karen McGovern et al. MOLECULAR CANCER THERAPEUTICS
- Discovery of isonucleotidic CDNs as potent STING agonists with immunomodulatory potential
- (2022) Milan Dejmek et al. STRUCTURE
- Insights into the dynamic interactions at chemokine-receptor interfaces and mechanistic models of chemokine binding
- (2022) Archana Sonawani et al. JOURNAL OF STRUCTURAL BIOLOGY
- The expanding role for small molecules in immuno-oncology
- (2022) Rienk Offringa et al. NATURE REVIEWS DRUG DISCOVERY
- Protein kinase inhibitor ceritinib blocks ectonucleotidase CD39 – a promising target for cancer immunotherapy
- (2022) Laura Schäkel et al. Journal for ImmunoTherapy of Cancer
- OATD-02 Validates the Benefits of Pharmacological Inhibition of Arginase 1 and 2 in Cancer
- (2022) Marcin Mikołaj Grzybowski et al. Cancers
- Insights into non-peptide small-molecule inhibitors of the PD-1/PD-L1 interaction: Development and perspective
- (2021) Xia Wu et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Alterations of DNA damage response pathway: Biomarker and therapeutic strategy for cancer immunotherapy
- (2021) Minlin Jiang et al. Acta Pharmaceutica Sinica B
- If Small Molecules Immunotherapy Comes, Can the Prime be Far Behind?
- (2021) Jingyu Zhang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapy
- (2021) Toni K. Choueiri et al. INVESTIGATIONAL NEW DRUGS
- Impact of long-term ibrutinib treatment on circulating immune cells in previously untreated chronic lymphocytic leukemia
- (2021) Isabelle G. Solman et al. LEUKEMIA RESEARCH
- Application of immune checkpoint targets in the anti-tumor novel drugs and traditional Chinese medicine development
- (2021) Yuli Wang et al. Acta Pharmaceutica Sinica B
- Innate and adaptive immune responses toward nanomedicines
- (2021) Iara Maíra de Oliveira Viana et al. Acta Pharmaceutica Sinica B
- Small molecule inhibitors against PD-1/PD-L1 immune checkpoints and current methodologies for their development: a review
- (2021) Chang Liu et al. Cancer Cell International
- Pembrolizumab plus axitinib for the treatment of advanced renal cell carcinoma
- (2021) Martina Spisarová et al. Expert Review of Anticancer Therapy
- Thinking Small: Small Molecules as Potential Synergistic Adjuncts to Checkpoint Inhibition in Melanoma
- (2021) Alexander C. Chacon et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Advances in immunotherapy for hepatocellular carcinoma
- (2021) Bruno Sangro et al. Nature Reviews Gastroenterology & Hepatology
- Salmonella flagella confer anti-tumor immunological effect via activating Flagellin/TLR5 signalling within tumor microenvironment
- (2021) Jianxiang Chen et al. Acta Pharmaceutica Sinica B
- Tubeimoside-1 induces TFEB-dependent lysosomal degradation of PD-L1 and promotes antitumor immunity by targeting mTOR
- (2021) Xiaojia Liu et al. Acta Pharmaceutica Sinica B
- MO10-6 Phase 1 study of retifanlimab (anti-PD-1) and INCB001158 (arginase inhibitor), alone or in combination, in solid tumors
- (2021) Takafumi Koyama et al. ANNALS OF ONCOLOGY
- Latest update on chemokine receptors as therapeutic targets
- (2021) Wing Yee Lai et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- In vitro and in vivo degradation of programmed cell death ligand 1 (PD-L1) by a proteolysis targeting chimera (PROTAC)
- (2021) Yubo Wang et al. BIOORGANIC CHEMISTRY
- A phase I study of an IDO inhibitor (SHR9146) plus camrelizumab and in combination with/without apatinib in patients with advanced solid tumors: Safety and efficacy analysis.
- (2021) Ying Cheng et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 1 trial of the adenosine A2A receptor antagonist inupadenant (EOS-850): Update on tolerability, and antitumor activity potentially associated with the expression of the A2A receptor within the tumor.
- (2021) Laurence Buisseret et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 1 clinical trial of the PI3Kδ inhibitor YY-20394 in patients with B-cell hematological malignancies
- (2021) Bo Jiang et al. Journal of Hematology & Oncology
- Structure-Based Design of Highly Potent Toll-like Receptor 7/8 Dual Agonists for Cancer Immunotherapy
- (2021) Zhisong Wang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Design, Synthesis, and Structure–Activity Relationship of N-Aryl-N′-(thiophen-2-yl)thiourea Derivatives as Novel and Specific Human TLR1/2 Agonists for Potential Cancer Immunotherapy
- (2021) Zhipeng Chen et al. JOURNAL OF MEDICINAL CHEMISTRY
- Novel Biphenyl Pyridines as Potent Small-Molecule Inhibitors Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction
- (2021) Tianyu Wang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Topical arginase inhibition decreases growth of cutaneous squamous cell carcinoma
- (2021) Amit Mittal et al. Scientific Reports
- Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma
- (2021) Yousef Zakharia et al. Journal for ImmunoTherapy of Cancer
- Multifaceted Immunomodulatory Effects of the BTK Inhibitors Ibrutinib and Acalabrutinib on Different Immune Cell Subsets – Beyond B Lymphocytes
- (2021) Sining Zhu et al. Frontiers in Cell and Developmental Biology
- PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy
- (2021) Pottayil G. Sasikumar et al. Communications Biology
- IDO1/TDO dual inhibitor RY103 targets Kyn-AhR pathway and exhibits preclinical efficacy on pancreatic cancer
- (2021) Heng Liang et al. CANCER LETTERS
- Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas
- (2021) Funda Meric-Bernstam et al. CLINICAL CANCER RESEARCH
- Discovery of novel BTK PROTACs for B-Cell lymphomas
- (2021) Yunpeng Zhao et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of tert-amine-based RORγt agonists
- (2021) Ruomeng Qiu et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of novel N-sulfonamide-tetrahydroisoquinolines as potent retinoic acid receptor-related orphan receptor γt agonists
- (2021) Xiaojun Ma et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Conjugate of ibrutinib with a TLR7 agonist suppresses melanoma progression and enhances antitumor immunity
- (2021) Sumei Ren et al. International Journal of Biological Sciences
- Discovery of the First Potent IDO1/IDO2 Dual Inhibitors: A Promising Strategy for Cancer Immunotherapy
- (2021) Xin He et al. JOURNAL OF MEDICINAL CHEMISTRY
- Advance investigation on synthetic small-molecule inhibitors targeting PD-1/PD-L1 signaling pathway
- (2021) Annoor Awadasseid et al. LIFE SCIENCES
- BMS-813160: A Potent CCR2 and CCR5 Dual Antagonist Selected as a Clinical Candidate
- (2021) Robert J. Cherney et al. ACS Medicinal Chemistry Letters
- PI3Kδ Inhibitors as Immunomodulatory Agents for the Treatment of Lymphoma Patients
- (2021) Chiara Tarantelli et al. Cancers
- Toll-Like Receptors as a Therapeutic Target in the Era of Immunotherapies
- (2021) Mariya Farooq et al. Frontiers in Cell and Developmental Biology
- Clinical significance of chemokine receptor antagonists
- (2020) Miao Miao et al. Expert Opinion on Drug Metabolism & Toxicology
- IDO Targeting in Sarcoma: Biological and Clinical Implications
- (2020) Imane Nafia et al. Frontiers in Immunology
- Discovery of the first potent proteolysis targeting chimera (PROTAC) degrader of indoleamine 2, 3-dioxygenase 1
- (2020) Mingxing Hu et al. Acta Pharmaceutica Sinica B
- The CCR5 antagonist maraviroc causes remission of pancreatic cancer liver metastasis in nude rats based on cell cycle inhibition and apoptosis induction
- (2020) Huiying Huang et al. CANCER LETTERS
- Discovery of Potent and Selective Non-Nucleotide Small Molecule Inhibitors of CD73
- (2020) Joel W. Beatty et al. JOURNAL OF MEDICINAL CHEMISTRY
- Small molecules, big impact: 20 years of targeted therapy in oncology
- (2020) Philippe L Bedard et al. LANCET
- Discovery and Optimization of Rationally Designed Bicyclic Inhibitors of Human Arginase to Enhance Cancer Immunotherapy
- (2020) Matthew J. Mitcheltree et al. ACS Medicinal Chemistry Letters
- CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers
- (2020) Jerry B. Harvey et al. Frontiers in Immunology
- Small molecules targeting the innate immune cGAS‒STING‒TBK1 signaling pathway
- (2020) Chunyong Ding et al. Acta Pharmaceutica Sinica B
- Substituted benzyloxytricyclic compounds as retinoic acid-related orphan receptor gamma t (RORγt) agonists
- (2020) Lalgudi S. Harikrishnan et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Design, synthesis and biological activity evaluation of novel 4-((1-cyclopropyl-3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl) oxy) pyridine-2-yl) amino derivatives as potent transforming growth factor-β (TGF-β) type I receptor inhibitors
- (2020) Bin Tan et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Design, synthesis, and evaluation of novel CXCR4 antagonists based on an aminoquinoline template
- (2020) Yu Lin et al. BIOORGANIC CHEMISTRY
- Safety, Pharmacokinetics, and Pharmacodynamics of the TLR4 Agonist GSK1795091 in Healthy Individuals: Results from a Randomized, Double-blind, Placebo-controlled, Ascending Dose Study
- (2020) Bruce A. Hug et al. CLINICAL THERAPEUTICS
- Discovery of indoximod prodrugs and characterization of clinical candidate NLG802
- (2020) Sanjeev Kumar et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Synthesis and biological evaluation of 4-(pyridin-4-oxy)-3-(3,3-difluorocyclobutyl)-pyrazole derivatives as novel potent transforming growth factor-β type 1 receptor inhibitors
- (2020) Guofeng Xu et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of novel resorcinol diphenyl ether-based PROTAC-like molecules as dual inhibitors and degraders of PD-L1
- (2020) Binbin Cheng et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Novel Piperidinyl-Azetidines as Potent and Selective CCR4 Antagonists Elicit Antitumor Response as a Single Agent and in Combination with Checkpoint Inhibitors
- (2020) Omar Robles et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of Novel Resorcinol Dibenzyl Ethers Targeting the Programmed Cell Death-1/Programmed Cell Death–Ligand 1 Interaction as Potential Anticancer Agents
- (2020) Binbin Cheng et al. JOURNAL OF MEDICINAL CHEMISTRY
- Ibrutinib Restores Immune Cell Numbers and Function in First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia
- (2020) Isabelle G. Solman et al. LEUKEMIA RESEARCH
- Opportunities for Small Molecules in Cancer Immunotherapy
- (2020) Sabina Y. van der Zanden et al. TRENDS IN IMMUNOLOGY
- Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine
- (2020) Luis Felipe Campesato et al. Nature Communications
- Small molecule AZD4635 inhibitor of A2AR signaling rescues immune cell function including CD103+ dendritic cells enhancing anti-tumor immunity
- (2020) Alexandra Borodovsky et al. Journal for ImmunoTherapy of Cancer
- Berberine diminishes cancer cell PD-L1 expression and facilitates antitumor immunity via inhibiting the deubiquitination activity of CSN5
- (2020) Yang Liu et al. Acta Pharmaceutica Sinica B
- Targeting castration-resistant prostate cancer with a novel RORγ antagonist elaiophylin
- (2020) Jianwei Zheng et al. Acta Pharmaceutica Sinica B
- The dual PI3Kδ/CK1ε inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells
- (2020) Kamira Maharaj et al. Blood Advances
- The therapeutic potential of targeting CD73 and CD73-derived adenosine in melanoma
- (2020) Anvar Soleimani et al. BIOCHIMIE
- Orally Bioavailable Small-Molecule CD73 Inhibitor (OP-5244) Reverses Immunosuppression through Blockade of Adenosine Production
- (2020) Xiaohui Du et al. JOURNAL OF MEDICINAL CHEMISTRY
- Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy
- (2020) Leilei Ai et al. Drug Design Development and Therapy
- Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors
- (2020) Lillian Siu et al. Journal for ImmunoTherapy of Cancer
- Design, synthesis, and biological evaluation of a novel indoleamine 2,3-dioxigenase 1 (IDO1) and thioredoxin reductase (TrxR) dual inhibitor
- (2020) Qing-Zhu Fan et al. BIOORGANIC CHEMISTRY
- Pharmacodynamics‐based approach for efficacious human dose projection of BMS‐986260, a small molecule transforming growth factor beta receptor 1 inhibitor
- (2020) Karen E. Parrish et al. BIOPHARMACEUTICS & DRUG DISPOSITION
- Design, synthesis and biological evaluation of novel scaffold benzo[4,5]imidazo [1,2-a]pyrazin-1-amine: Towards adenosine A2A receptor (A2A AR) antagonist
- (2020) G. Lakshma Reddy et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Antibody and antibody fragments for cancer immunotherapy
- (2020) Weizhi Chen et al. JOURNAL OF CONTROLLED RELEASE
- SHC014748M, a novel selective inhi-bitor of PI3Kδ, demonstrates promising preclinical antitumor activity in B cell lymphomas and chronic lymphocytic leukemia
- (2020) Lei Fan et al. NEOPLASIA
- Cancer stem cell-targeted chimeric antigen receptor (CAR)-T cell therapy: Challenges and prospects
- (2020) Javad Masoumi et al. Acta Pharmaceutica Sinica B
- Discovery of natural product ellagic acid as a potent CD73 and CD39 dual inhibitor
- (2020) Yuan Wang et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Design, synthesis, evaluation, and SAR of 4-phenylindoline derivatives, a novel class of small-molecule inhibitors of the programmed cell death-1/ programmed cell death-ligand 1 (PD-1/PD-L1) interaction
- (2020) Yang Yang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
- (2019) Xin Wang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Small-Molecule Immuno-Oncology Therapy: Advances, Challenges and New Directions
- (2019) Shulun Chen et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- Phase 1 Open-Label, Multicenter Study of First-in-Class RORγ Agonist LYC-55716: Safety, Tolerability, and Preliminary Evidence of Antitumor Activity
- (2019) Devalingam Mahalingam et al. CLINICAL CANCER RESEARCH
- Neutrophils and NETS in modulating acute and chronic inflammation
- (2019) Fernanda Vargas e Silva Castanheira et al. BLOOD
- Phase I study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumours
- (2019) Takahiro Ebata et al. INVESTIGATIONAL NEW DRUGS
- Discovery of [1,2,4]Triazolo[4,3-a]pyridines as Potent Inhibitors Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction
- (2019) Mingze Qin et al. JOURNAL OF MEDICINAL CHEMISTRY
- Recent Advances targeting CCR5 for Cancer and its Role in Immuno-Oncology
- (2019) Xuanmao Jiao et al. CANCER RESEARCH
- Cdk5 knocking out mediated by CRISPR-Cas9 genome editing for PD-L1 attenuation and enhanced antitumor immunity
- (2019) Huan Deng et al. Acta Pharmaceutica Sinica B
- The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma
- (2019) Yi‐Xin Zou et al. HEMATOLOGICAL ONCOLOGY
- Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
- (2019) Georgina V Long et al. LANCET ONCOLOGY
- Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape
- (2019) Arsen Osipov et al. Journal for ImmunoTherapy of Cancer
- Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses
- (2019) Xi Chen et al. Acta Pharmaceutica Sinica B
- Protective role of berberine on ulcerative colitis through modulating enteric glial cells–intestinal epithelial cells–immune cells interactions
- (2019) Heng Li et al. Acta Pharmaceutica Sinica B
- Cancer and the Immune System: The History and Background of Immunotherapy
- (2019) Maura Abbott et al. Seminars in Oncology Nursing
- Population pharmacokinetics of vactosertib, a new TGF-β receptor type Ι inhibitor, in patients with advanced solid tumors
- (2019) Su Young Jung et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Discovery of aryl-substituted indole and indoline derivatives as RORγt agonists
- (2019) Yan Zhu et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Progress in PD-1/PD-L1 pathway inhibitors: From biomacromolecules to small molecules
- (2019) Xin Lin et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models
- (2019) Sarah Greene et al. CLINICAL CANCER RESEARCH
- Amide-sulfamide modulators as effective anti-tumor metastatic agents targeting CXCR4/CXCL12 axis
- (2019) Rui Wu et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- ENERGIZE: a Phase III study of neoadjuvant chemotherapy alone or with nivolumab with/without linrodostat mesylate for muscle-invasive bladder cancer
- (2019) Guru Sonpavde et al. Future Oncology
- Long-Term Ibrutinib Therapy Reverses CD8+ T Cell Exhaustion in B Cell Chronic Lymphocytic Leukaemia
- (2019) Helen M. Parry et al. Frontiers in Immunology
- Immune Checkpoint PD-1/PD-L1: Is There Life Beyond Antibodies?
- (2018) Markella Konstantinidou et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Heterobicyclic inhibitors of transforming growth factor beta receptor I (TGFβRI)
- (2018) Lalgudi S. Harikrishnan et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Discovery and synthesis of 6,7,8,9-tetrahydro-5 H -pyrido[4,3- c ]azepin-5-one-based novel chemotype CCR2 antagonists via scaffold hopping strategy
- (2018) Li-Huai Qin et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
- (2018) Michael J. Overman et al. JOURNAL OF CLINICAL ONCOLOGY
- Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy
- (2018) Kui Li et al. JOURNAL OF DRUG TARGETING
- Plasmacytoid dendritic cell in immunity and cancer
- (2018) Dana Mitchell et al. JOURNAL OF NEUROIMMUNOLOGY
- Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study
- (2018) Howard A Burris et al. LANCET ONCOLOGY
- Targeting SHP-1, 2 and SHIP Pathways: A Novel Strategy for Cancer Treatment?
- (2018) Wolfram C.M. Dempke et al. ONCOLOGY
- Discovery of Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) and Histone Deacetylase (HDAC) Dual Inhibitors
- (2018) Kun Fang et al. ACS Medicinal Chemistry Letters
- Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies
- (2018) Arnon P. Kater et al. Blood Cancer Journal
- Cancer immunotherapy: broadening the scope of targetable tumours
- (2018) Jitske van den Bulk et al. Open Biology
- Abstract CT176: Effect of JAK/STAT or PI3Kδ plus PD-1 inhibition on the tumor microenvironment: Biomarker results from a phase Ib study in patients with advanced solid tumors
- (2018) John M. Kirkwood et al. CANCER RESEARCH
- Abstract 4726: Novel intravenous injectable TLR7 agonist, DSP-0509, synergistically enhanced antitumor immune responses in combination with anti-PD-1 antibody
- (2018) Yosuke Ota et al. CANCER RESEARCH
- Design, Synthesis, and Pharmacological Evaluation of Second-Generation Tetrahydroisoquinoline-Based CXCR4 Antagonists with Favorable ADME Properties
- (2018) Huy H. Nguyen et al. JOURNAL OF MEDICINAL CHEMISTRY
- Immunomodulators targeting the PD-1/PD-L1 protein-protein interaction: From antibodies to small molecules
- (2018) Jeffrey Yang et al. MEDICINAL RESEARCH REVIEWS
- Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond
- (2018) Alexander J. Muller et al. Seminars in Immunopathology
- LY2157299 Monohydrate, a TGF-βR1 Inhibitor, Suppresses Tumor Growth and Ascites Development in Ovarian Cancer
- (2018) Qing Zhang et al. Cancers
- LBA15Preliminary results of the first-in-human (FIH) study of MK-1454, an agonist of stimulator of interferon genes (STING), as monotherapy or in combination with pembrolizumab (pembro) in patients with advanced solid tumors or lymphomas
- (2018) K J Harrington et al. ANNALS OF ONCOLOGY
- Small molecules as PD-1/PD-L1 pathway modulators for cancer immunotherapy
- (2018) Peifu Jiao et al. CURRENT PHARMACEUTICAL DESIGN
- Safety, tolerability, and pharmacology of AB928, a novel dual adenosine receptor antagonist, in a randomized, phase 1 study in healthy volunteers
- (2018) Lisa Seitz et al. INVESTIGATIONAL NEW DRUGS
- Design of amidobenzimidazole STING receptor agonists with systemic activity
- (2018) Joshi M. Ramanjulu et al. NATURE
- Surgery Versus 5% Imiquimod for Nodular and Superficial Basal Cell Carcinoma: 5-Year Results of the SINS Randomized Controlled Trial
- (2017) Hywel C. Williams et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Discovery of Small Molecules as Multi-Toll-like Receptor Agonists with Proinflammatory and Anticancer Activities
- (2017) Lei Zhang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Dual enhancement of T and NK cell function by pulsatile inhibition of SHIP1 improves antitumor immunity and survival
- (2017) Matthew Gumbleton et al. Science Signaling
- Dual enhancement of T and NK cell function by pulsatile inhibition of SHIP1 improves antitumor immunity and survival
- (2017) Matthew Gumbleton et al. Science Signaling
- Synthetic RORγt Agonists Enhance Protective Immunity
- (2016) Mi Ra Chang et al. ACS Chemical Biology
- TGF-β Signaling in Cancer
- (2016) Viqar Syed JOURNAL OF CELLULAR BIOCHEMISTRY
- Synthetic RORγ agonists regulate multiple pathways to enhance antitumor immunity
- (2016) Xiao Hu et al. OncoImmunology
- Big opportunities for small molecules in immuno-oncology
- (2015) Jerry L. Adams et al. NATURE REVIEWS DRUG DISCOVERY
- A Phase I Dose-Finding Study of the Novel Toll-like Receptor 8 Agonist VTX-2337 in Adult Subjects with Advanced Solid Tumors or Lymphoma
- (2014) D. W. Northfelt et al. CLINICAL CANCER RESEARCH
- AS04, an Aluminum Salt- and TLR4 Agonist-Based Adjuvant System, Induces a Transient Localized Innate Immune Response Leading to Enhanced Adaptive Immunity
- (2009) A. M. Didierlaurent et al. JOURNAL OF IMMUNOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started